MIM
CLDX icon

Monashee Investment Management’s Celldex Therapeutics CLDX Stock Holding History

Monashee Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-87,500
Closed -$3.67M – 92
2024
Q1 		$3.67M Sell
87,500
-12,709
-13% -$522K 0.43% 42
2023
Q4 		$3.97M Buy
+100,209
New +$2.95M 0.7% 14
2020
Q3 		– Sell
-300,000
Closed -$3.9M – 192
2020
Q2 		$3.9M Buy
+300,000
New +$1.33M 0.58% 51
2015
Q2 		– Sell
-1,333
Closed -$557K – 78
2015
Q1 		$557K Buy
+1,333
New +$477K 0.35% 56

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Monashee Investment Management's CLDX Position: Q2 2024 in Review

Monashee Investment Management sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 87,500 shares — an estimated $3.67M sold.

Monashee Investment Management first reported a position in CLDX in Q1 2015 and held it in 4 quarters. The position peaked at $3.97M in Q4 2023. 183 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

  • Monashee Investment Management reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Monashee Investment Management sold 87,500 Celldex Therapeutics shares in Q2 2024, an estimated $3.67M.
  • Monashee Investment Management first reported a position in Celldex Therapeutics in Q1 2015 and held it in 4 quarters.
  • Monashee Investment Management's Celldex Therapeutics position peaked at $3.97M in Q4 2023.
  • 183 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on Monashee Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.